• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail

Important Warnings and Instructions for Heparin Sodium Injection (Baxter) - Overview

Listen to this Podcast

 

Transcript
Run Time -- 00:05:15

Welcome to the Food and Drug Administration's drug safety update.

I am Pat Clarke from F-D-A's Center for Drug Evaluation and Research.

On February 11, 2008 we issued a public health advisory titled: Important Warnings and Instructions for Heparin Sodium Injection (Baxter).

FDA is issuing this alert to:

  • inform the public about reports of serious adverse events in patients who received bolus injections of heparin sodium for injection primarily from multiple-dose vials manufactured by Baxter Healthcare Corporation, and to
  • recommend measures that may help to minimize these risks if this product must be used due to medical necessity.

A bolus injection means the injection of a drug or drugs in a high quantity at once, the opposite of gradual administration.

Heparin sodium is an anticoagulant, also known as a blood thinner that is commonly administered intravenously. It is used in patients undergoing kidney dialysis, certain types of cardiac surgery, and treatment or prevention of other serious medical conditions, including deep venous thrombosis and pulmonary emboli. In many settings heparin treatment is initiated using high doses of five thousand to fifty thousand units given directly into the blood stream intravenously as a bolus.

Serious adverse events have recently been reported in patients who received these higher bolus doses. The serious adverse events include allergic or hypersensitivity-type reactions, with symptoms of oral swelling, nausea, vomiting, sweating, shortness of breath, and cases of severe hypotension requiring treatment. Most events developed within minutes of heparin initiation although the possibility for a delayed response has not been excluded. The reports have largely involved use of multiple-dose vials. However there have been several cases in which product from multiple, single-dose vials have been combined to administer a bolus dose.

 

Heparin is also used in other clinical settings at lower doses or over longer periods of time; adverse events like those described above have not been seen with those uses. FDA is currently investigating whether similar adverse events have been reported for heparin products from other manufacturers.

Because of concern about the occurrence of these serious adverse events, Baxter has temporarily suspended manufacture of its multiple-dose vials of heparin sodium pending the completion of an extensive ongoing investigation to determine the root cause of the problem. Heparin is a medically necessary product and serious public health consequences would result if there were a sudden shortage of the drug. Therefore, Baxter and FDA agree that multiple-dose vials of heparin manufactured by Baxter that are currently in distribution will not be recalled. These vials may be used with caution in situations where alternative products are either not available or would be inappropriate for the individual medical situation.

FDA is providing the following recommendations to physicians, dialysis center staff, and other health care providers when using heparin sodium for injection.

  • When bolus use is required, try to use a heparin product from another manufacturer or an alternate anticoagulant
  • When Baxter product is the only heparin product available and use of heparin is considered to be medically necessary:
    • Administer infusions without using a bolus dose whenever possible
    • Use the lowest dose necessary at the slowest infusion rate acceptable to obtain the desired effect
    • Closely monitor the patient for adverse events, particularly hypotension and signs and symptoms of hypersensitivity, and ensure that resuscitation equipment is available
    • Consider the potential risks and benefits in individual patients of pretreatment with corticosteroids or antihistamines before the heparin is administered. At this time FDA does not have data to determine if such pretreatment is effective.

To hear the full public health advisory, listen to part two of this broadcast.

Health care providers should report any allergic-type reaction to heparin infusion to FDA's MedWatch on-line at F-D-A dot GOV slash M-E-D-W-A-T-C-H slash R-E-P-O-R-T slash H-C-P dot HTM, http://www.fda.gov/medwatch/report/hcp.htm , by fax at 1-800-FDA-0178, by mail using the postage-paid address form provided on-line, or by telephone at 1-800-F-D-A-ten-88.

 

Date created: February 13, 2008

 

Contact FDA

1-800-332-1088
1-800-FDA-0178 Fax
Report a Serious Problem

MedWatch Online

Regular Mail: Use postage-paid FDA Form 3500

Mail to: MedWatch 5600 Fishers Lane

Rockville, MD 20857